2023 Surgical Oncology Cancer Symposium
The University of Tennessee Health Science Center Division of Surgical Oncology is hosting a one-day symposium on the management of colorectal cancer. The purpose of this activity is to provide healthcare providers with up-to-date strategies in the evaluation and management of patients with localized and metastatic colorectal cancer. The symposium will provide a unique opportunity for clinicians involved in the care of these patients to learn from and interact with leading national and local faculty to increase clinical knowledge, apply new data into practice, and ultimately improve patient outcomes.
Target Audience
- Medical Oncologists
- Radiation Oncologists
- Surgeons (oncology, colorectal, general, hepatobiliary)
- Gastroenterologists
- Radiologists
- Pathologists
- Genetic Counselors
- Physicians
- Allied Health Professionals
- Residents
- Fellows
- Nurses
- Medical Students
Professional Practice Gap
Colorectal cancer remains among the most commonly diagnosed cancers and is responsible for a high proportion of cancer-related deaths in the United States. Over the last decade, there have been significant updates in the treatment of these patients. With the advent of total neoadjuvant therapy for rectal cancer, it is essential for clinicians to recognize nuances that influence the sequencing of chemotherapy and chemoradiation for these patients. In addition, understanding the evaluation and surveillance for rectal cancer patients who may be candidates for a “watch and wait” approach is important. Also, it is important that clinicians appreciate the evolving role of ctDNA in surveillance and treatment of colorectal cancer patients. Moreover, it is essential to appreciate how microsatellite status and mutational profiling inform appropriate utilization of immunotherapy and targeted therapies in colorectal cancer. Finally, having an appreciation for the role of metastasectomy for patients with stage IV disease and how surgery can improve survival in appropriately selected patients is critical to optimizing outcomes. This symposium is designed to give providers of all levels a contemporary perspective on the multidisciplinary management of colorectal cancer patients.
Learning Objectives
- Review evolving strategies in total neoadjuvant chemotherapy for rectal cancer, including updates in recent clinical trials.
- Recognize when and how to perform screening for hereditary conditions in patients with colorectal cancer.
- Appreciate the indications and outcomes for immunotherapy in patients with colorectal cancer.
- Describe the application of circulating tumor DNA in the surveillance and treatment decisions in patients with colorectal cancer.
- Review the utility of biologic therapies in colorectal cancer, understanding what agents to use and when to use them.
- Discuss the role of surgical management for patients with metastatic colorectal cancer.
*** This live activity has been approved for up to 6 AMA PRA Category 1 CreditsTM. ****
2023 Surgical Oncology Cancer Symposium: State of the Art Management Colorectal Cancer | |||
Saturday, September 30, 2023 | |||
Timeslot | Presentation # | Presentation | Presenter |
7:30 AM - 8:00 AM | N/A | Continental Breakfast | |
7:50 AM - 8:00 AM | N/A | Introduction / Opening Remarks | Paxton Dickson, MD |
8:00 AM - 8:20 AM | 1 | Current Concepts in Chemotherapy for Rectal Cancer | Hanna Sanoff, MD, MPH |
8:20 AM - 8:40 AM | 2 | Radiation Therapy: When and For How Long? | Sarah Hoffe, MD |
8:40 AM -9:00 AM | 3 | Watch and Wait - Where are We in 2023? | David Shibata, MD |
9:00 AM - 9:20 AM | 4 | Germline Testing for Colorectal Cancer - When is it Necessary? | Bryson Katona, MD, PhD |
9:20 AM - 9:40 AM | Question and Answer | ||
9:40 AM - 10:00 AM | N/A | Break | |
10:00 AM - 11:00 AM | 5 | Case-Based Multidisciplinary Panel Discussion: Rectal Cancer | N/A |
11:00 PM - 11:40 PM | N/A | Lunch / Visit with Exhibitors | |
11:40 AM - 12:00 PM | 6 | Immunotherapy in Colorectal Cancer | Andrea Cercek, MD |
12:00 PM - 12:20 PM | 7 | Real World Application for ctDNA in Colorectal Cancer | Van Morris, MD |
12:20 PM - 12:40 PM | Question and Answer | ||
12:40 PM - 12:50 PM | N/A | Break | |
12:50 PM - 1:10 PM | 8 | Biologic Therapies - What and When? | Saurin Chokshi, MD |
1:10 PM - 1:30 PM | 9 | Contemporary Management of Liver Metastases | Ching-Wei Tzeng, MD |
1:30 PM - 1:50 PM | 10 | CRS and HIPEC in Colorectal Cancer Indications and Outcomes | Ian Solsky, MD |
1:50 PM - 2:10 PM | Question and Answer | ||
2:10 PM - 2:20 PM | N/A | Break | |
2:20 PM - 3:20 PM | 11 | Case-Based Multidisciplinary Panel Discussion: Management of Metastatic Disease | N/A |
3:20 PM - 3:30 PM | N/A | Closing Remarks and Adjournment | Paxton Dickson, MD |
Total CME | 6 hours |
Parking Map
Paxton V Dickson
AMA Credit Designation: The University of Tennessee College of Medicine (UTCOM) designates this live activity for a maximum of
6 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Education for Non-Physicians: The UTCOM will issue Certificates of Participation to non-physicians for participating in this activity and designates it for CEUs using the national standard that 1 hour of educational instruction is awarded .1 CEU.
Accreditation: The UTCOM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 6.00 AMA PRA Category 1 Credit™
- 6.00 Attendance